OBJECTIVES: To assess whether regulatory guidance on the use of dexamethasone in hospitalised COVID-19 patients is applicable to the larger population of COVID-19 cases. The surge in worldwide demand for dexamethasone suggests that the guidance, although correct, has not emphasised the danger of its wider use. STUDY DESIGN: Data from the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial and the World Health Organisation (WHO) prospective meta-analysis have been deconstructed and analysed. METHODS: To provide context, relevant publications were identified in PubMed using the following keywords: COVID-19, RECOVERY trial, WHO meta-analysis, variants, immunity, public health. RESULTS: The WHO guidance 'Corticosteroids for COVID-19' was based on their prospective meta-analysis. This meta-analysis was weighted by data from the RECOVERY trial. CONCLUSIONS: In terms of COVID-19, dexamethasone has value in a narrow indication, namely, in hospitalised patients requiring respiratory support. The media blitz likely resulted in the wider use of dexamethasone in outpatients and as a preventive medication. This is reflected in the surge in worldwide demand for dexamethasone. We ask whether the use of steroids, beyond regulatory indications, may be responsible for the recent increase in mortality and especially the emergence of mucormycosis? From the public health standpoint, the current guidance for use of dexamethasone in COVID-19 could benefit from clarification and the addition of a cautionary note.

Department of Cell Biology Charles University Viničná 7 Prague Czech Republic; Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University Průmyslová 595 Vestec U Prahy 25242 Czech Republic

Medbase 114 Milton Avenue Chapel Hill NC 27514 USA

See more in PubMed

Oxford University . Press release; June 16, 2020. Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19.https://www.recoverytrial.net/files/recovery_dexamethasone_statement_160620_v2final.pdf

RECOVERY Collaborative Group Dexamethasone in hospitalized patients with covid-19 - preliminary report. N Engl J Med. 2021;364:693–704. PubMed PMC

Ledford H. Coronavirus breakthrough: dexamethasone is the first drug shown to save lives. Nature. 2020;582:469. PubMed

Prescott H.C., Rice T.W. Editorial. Corticosteroids in COVID-19 ARDS: evidence and hope during the pandemic. JAMA. 2020;324:1292–1295. PubMed

Mather N. How we accelerated clinical trials in the age of COVID-19. Nature. 2020;584:326. PubMed

The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19. A meta-analysis. JAMA. 2020;324:1330–1341. PubMed PMC

Living Guidance . September 2, 2020. Corticosteroids for COVID-19. World Health Organisation.https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1 WHO reference number: WHO/2019-nCoV/Corticosteroids/2020.1.

Holmberg M.J., Andersen L.W. Estimating risk ratios and risk differences: alternatives to Odds Ratios. JAMA. 2020;324:1098–1099. PubMed

de Grooth H.J., Parienti J.J., Oudemans-van Straaten H.M. Should we rely on trials with disease- rather than patient-oriented endpoints? Intensive Care Med. 2018;44:464–466. PubMed PMC

Newcombe R.G., Altman D.G. Statistics with confidence. 2nd ed. Ch 6. BMJ Books; 2000. Proportions and their differences.

Kupferschmidt K. One U.K. trial is transforming COVID-19 treatment. Why haven't others delivered more results? Science. 2020;369:124–125. doi: 10.1126/science.abd6417. PubMed DOI

Normand S.T. The RECOVERY platform. N Engl J Med. 2021;384:757–758. PubMed PMC

Villar J., Blanco J., Zhang H., Slutsky A.S. Ventilator-induced lung injury and sepsis: two sides of the same coin? Minerva Anestesiol. 2011;77:647–653. PubMed

Reis F.F., Reboredo Mde M., Lucinda L.M., Bianchi A.M., Rabelo M.A., Fonseca L.M. Pre-treatment with dexamethasone attenuates experimental ventilator-induced lung injury. J Bras Pneumol. 2016;42:166–173. PubMed PMC

Slutsky A.S., Tremblay L.N. Multiple system organ failure: is mechanical ventilation a contributing factor? Am J Respir Crit Care Med. 1998;157:1721–1725. PubMed

Halbertsma F.J.J., Vaneker M., Scheffer G.J., van der Hoeven J.G. Cytokines and biotrauma in ventilator-induced lung injury: a critical review of the literature. Neth J Med. 2005;63:382–392. PubMed

Hartmann S.M., Hough C.L. Argument against the routine use of steroids for pediatric acute respiratory distress syndrome. Front Pediatr. 2016;4:79. PubMed PMC

Zhang Z., Chen L., Ni H. The effectiveness of corticosteroids on mortality in patients with acute respiratory distress syndrome or acute lung injury: a secondary analysis. Sci Rep. 2015;5:17654. PubMed PMC

Meduri G.U., Siemieniuk R.A.C., Ness R.A., Seyler S.J. Prolonged low-dose methylprednisolone treatment is highly effective in reducing duration of mechanical ventilation and mortality in patients with ARDS. J Intensive Care. 2018;6:53. PubMed PMC

Slutsky A.S., Ranieri V.M. Ventilator-induced lung injury. N Engl J Med. 2013;369:2126–2136. PubMed

Madahar P., Beitler J.R. Emerging concepts in ventilation-induced lung injury. F1000Research. 2020;9:222. PubMed PMC

Wilson M.R., Takata M. Inflammatory mechanisms of ventilator-induced lung injury: a time to stop and think? Anaesthesia. 2013;68:175–178. PubMed

Moloney E.D., Griffiths M.J.D. Protective ventilation of patients with acute respiratory distress syndrome. BJA. 2004;92:261–270. PubMed

Curley G.F., Laffey J.G., Zhang H., Slutsky A.S. Biotrauma and ventilator induced lung injury: clinical implications. Chest. 2016;150:1109–1117. PubMed

Villar J., Confalonieri M., Pastores S.M., Meduri G.U. Rationale for prolonged corticosteroid treatment in the acute respiratory distress syndrome caused by coronavirus disease 2019. Crit Care Expl. 2020;2 PubMed PMC

Yang Z., Liu J., Zhou Y., Zhao X., Zhao Q., Liu J. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect. 2020;81:13–20. PubMed PMC

Ni Y.N., Chen G., Sun J., Liang B.M., Liang Z.A. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Crit Care. 2020;23:99. PubMed PMC

Arabi Y.M., Mandourah Y., Al-Hameed F., Sindi A.A., Almekhlafi G.A., Hussein M.A. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med. 2018;197:757–767. PubMed

Thomas B.J., Porritt R.A., Hertzog P.J., Bardin P.G., Tate M.D. Glucocorticosteroids enhance replication of respiratory viruses: effect of adjuvant interferon. Sci Rep. 2020;4:7176. PubMed PMC

Lee N., Allen Chan K.C., Hui D.S., Ng E.K.O., Wu A., Chiu R.W.K. Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients. J Clin Virol. 2004;31:304–309. PubMed PMC

Hui D.S. Systemic corticosteroid therapy may delay viral clearance in patients with Middle East Respiratory Syndrome coronavirus infection. Am J Respir Crit Care Med. 2018;197:700–701. PubMed

Li H., Chen C., Hu F., Wang J., Zhao Q., Gale R.P. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis. Leukemia. 2020;34:1503–1511. PubMed PMC

Liu J., Zhang S., Dong X., Li Z., Xu Q., Feng H. Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome. J Clin Invest. 2020;130:6417–6428. PubMed PMC

Matthay M.A., Wick K.D. Corticosteroids, COVID-19 pneumonia, and acute respiratory distress syndrome. J Clin Invest. 2020;130:6218–6221. PubMed PMC

Fujishima S. COVID-19: stay cool toward corticosteroids. Keio J Med. 2020;69:27–29. PubMed

Russell C.D., Millar J.E., Baillie J.K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473–475. PubMed PMC

Sarkar S., Khanna P., Soni K.D. Are the steroids a blanket solution for COVID-19? A systematic review and meta-analysis. J Med Virol. 2021;93:1538–1547. PubMed

Zha L., Li S., Pan L., Tefsen B., Li Y., French N. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19) MJA. 2020;212:416–420. PubMed PMC

Cao B., Gao H., Zhou B., Deng X., Hu C., Deng C. Adjuvant corticosteroid treatment in adults with influenza A (H7N9) viral pneumonia. Crit Care Med. 2016;44:318–328. PubMed

Gola G.F., Bruttomesso A.C., Barquero A.A., Ramírez J.A. The new role of steroids in viral infections. Front Clin Drug Res - Anti-Infectives. 2017;4:274–322.

Shoemark D.K., Colenso C.K., Toelzer C., Gupta K., Sessions R.B., Davidson A.D. Molecular simulations suggest vitamins, retinoids and steroids as ligands of the free fatty acid pocket of the SARS-CoV-2 Spike protein. Angew Chem Int Ed. 2021;60:7098–7110. PubMed PMC

Amor S., Fernández Blanco L., Baker D. Innate immunity during SARS-CoV-2: evasion strategies and activation trigger hypoxia and vascular damage. Clin Exp Immunol. 2020;202:193–209. PubMed PMC

Sette A., Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184:861–880. PubMed PMC

Cohen J. An ‘uncoordinated’ immune response may explain why COVID-19 strikes some hard, particularly the elderly. Science. September 16, 2020 doi: 10.1126/science.abe8097. DOI

Wu K.J., Corum J. The New York Times; October 5, 2020. Charting a coronavirus infection.

Wadman M. Flawed interferon response spurs severe illness. Science. 2020;369:1550–1551. PubMed

Park A., Iwasaki A. Type I and Type III interferons – induction, signaling, evasion, and application to combat COVID-19. Cell Host Microbe. 2020;27:870–878. PubMed PMC

Flammer J.R., Dobrovolna J., Kennedy M.A., Chinenov Y., Glass C.K., Ivashkiv L.B. The type I interferon signaling pathway is a target for glucocorticoid inhibition. Mol Cell Biol. 2010;30:4564–4574. PubMed PMC

Thomas B.J., Porritt R.A., Hertzog P.J., Bardin P.G., Tate M.D. Glucocorticosteroids enhance replication of respiratory viruses: effect of adjuvant interferon. Sci Rep. 2014;4:7176. doi: 10.1038/srep07176. PubMed DOI PMC

Jalkanen J., Pettilä V., Huttunen T., Hollmén M., Jalkanen S. Glucocorticoids inhibit type I IFN beta signaling and the upregulation of CD73 in human lung. Intensive Care Med. 2020;46:1937–1940. PubMed PMC

Choi B., Choudhary M.C., Regan J., Sparks J.A., Padera R.F., Qiu X. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med. 2020;383:2291–2293. PubMed PMC

Mandavilli A. The New York Times; March 15, 2021. Virus variants likely evolved inside people with weak immune systems.

Lauring A.S., Hodcroft E.B. Genetic variants of SARS-CoV-2—what do they mean? JAMA. 2021;325:529–531. PubMed

Kemp S.A., Collier D.A., Gupta R.K. SARS-CoV-2 evolution during treatment of chronic infection. Nature. 2021 Feb 5 doi: 10.1038/s41586-021-03291-y. PubMed DOI PMC

van Oosterhout C., Hall N., Ly H., Tyler K.M. Editorial. COVID-19 evolution during the pandemic – implications of new SARS-CoV-2 variants on disease control and public health policies. Virulence. 2021;12:507–508. PubMed PMC

Weisblum Y., Schmidt F., Zhang F., DaSilva J., Poston D., Lorenzi J.C.C. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. eLife. 2020;9 doi: 10.7554/eLife.61312. PubMed DOI PMC

Prévost J., Finzi A. The great escape? SARS-CoV-2 variants evading neutralizing responses. Cell Host Microbe. 2021;29:322–324. PubMed PMC

Burki T. Understanding variants of SARS-CoV-2. Lancet. 2021;397:462. PubMed PMC

Cooper V. The coronavirus variants don't seem to be highly variable so far. Sci Am. March 24, 2021;32(2) https://www.scientificamerican.com/article/the-coronavirus-variants-dont-seem-to-be-highly-variable-so-far/

Karim S.S.A., de Oliveira T. New SARS-CoV-2 Variants — clinical, public health, and vaccine implications. N Engl J Med. 2021 doi: 10.1056/NEJMc2100362. PubMed DOI PMC

Rabin R.C. The New York Times; June 24, 2020. Breakthrough drug for Covid-19 may be risky for mild cases.

Perico N., Suter F., Remuzzi G. A recurrent question from a primary care physician: how should I treat my COVID-19 patients at home? Clin Med Invest. 2020;5:1–8.

Standard US citation for newspaper. Hopkins J.S. Wall Street Journal; 25 June 2020. Dexamethasone demand soars after positive Covid-19 Study.https://www.wsj.com/articles/dexamethasone-demand-soars-after-positive-covid-19-study-11593079202

Kuchler H. Financial Times; June 25, 2020. US hospital orders soar for Covid-19 steroid treatment.

Mahase E. Covid-19: demand for dexamethasone surges as RECOVERY trial publishes preprint. BMJ. 2020;369 PubMed

Lim M.A., Pranata R. Worrying situation regarding the use of dexamethasone for COVID-19. Ther Adv Respir Dis. 2020;14 PubMed PMC

Kansteiner F. With dexamethasone's sudden COVID-19 blessing, U.S. steroid supplies plummet. Fierce Pharma. June 25, 2020 https://www.fiercepharma.com/manufacturing/dexamethasone-s-rise-u-s-steroid-supplies-plummet

Tomazini B.M., Maia I.S., Cavalcanti A.B., Berwanger O., Rosa R.G., Veiga V.C. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19. The CoDEX Randomized Clinical Trial. JAMA. 2020;324:1307–1316. PubMed PMC

Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–1242. PubMed

Jordan R.E., Adab P., Cheng K.K. Covid-19: risk factors for severe disease and death. BMJ. 2020;368 doi: 10.1136/bmj.m1198. PubMed DOI

Editorial Curing COVID-19. Lancet Infect Dis. 2020;20:1101. PubMed PMC

Hotchkiss R.S., Moldawer L.L., Opal S.M. Sepsis and septic shock. Nat Rev Dis Primers. 2016;2:16045. doi: 10.1038/nrdp.2016.45. PubMed DOI PMC

Wadman M., Couzin-Frankel J., Kaiser J., Matacic C. A rampage through the body. Science. 2020;368:356–360. PubMed

Moore J.B., June C.H. Cytokine release syndrome in severe COVID-19. Science. 2020;368:473–474. PubMed

Smetana K., Rosel D., Brabek J. Raloxifene and Bazedoxifene could be promising candidates for preventing the COVID-19 related cytokine storm, ARDS and mortality. In Vivo. 2020;34:3027–3028. PubMed PMC

Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–1034. PubMed PMC

Buszko M., Park J.-H., Verthelyi D., Sen R., Young H.A., Rosenberg A.S. The dynamic changes in cytokine responses in COVID-19: a snapshot of the current state of knowledge. Nat Immunol. 2020;21:1146–1151. PubMed

van de Veerdonk F., Netea M.G., van Deuren M., van der Meer J.W., de Mast Q., Bruggemann R.J. Kinins and Cytokines in COVID-19: a comprehensive pathophysiological approach. Preprints. 2020 doi: 10.20944/preprints202004.0023.v1. DOI

Garvin M.R., Alvarez C., Miller J.I., Prates E.T., Walker A.M., Amos B.K. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. eLife. 2020;9 PubMed PMC

van de Veerdonk F.L., Netea M.G., van Deuren M., van der Meer J.W., de Mast Q., Brüggemann R.J. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. Elife. 2020;9 PubMed PMC

Conway E.M., Pryzdial E.L.G. Is the COVID-19 thrombotic catastrophe complement-connected? J Thromb Haemost. 2020;18:2812–2822. PubMed PMC

Polycarpou A., Howard M., Farrar C.A., Greenlaw R., Fanelli G., Wallis R. Rationale for targeting complement in COVID-19. EMBO Mol Med. 2020;12 doi: 10.15252/emmm.202012642. PubMed DOI PMC

Maglakelidze N., Manto K.M., Craig T.J. A Review: does complement or the contact system have a role in protection or pathogenesis of COVID-19? Pulm Ther. 2020;6:169–176. PubMed PMC

Risitano A.M., Mastellos D.C., Huber-Lang M., Yancopoulou D., Garlanda C., Ciceri F. Complement as a target in COVID-19? Nat Rev Immunol. 2020;20:343–344. PubMed PMC

Lo M.W., Kemper C., Woodruff T.M. COVID-19: complement, coagulation, and collateral damage. J Immunol. 2020;205:1488–1495. PubMed PMC

Iba T., Connors J.M., Levy J.H. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflamm Res. 2020;69:1181–1189. PubMed PMC

Shatzel J.J., DeLoughery E.P., Lorentz C.U., Tucker E.I., Aslan J.E., Hinds M.T. The contact activation system as a potential therapeutic target in patients with COVID-19. Res Pract Thromb Haemost. 2020;4:500–505. PubMed PMC

Middleton E.A., He X.-Y., Denorme F., Campbell R.A., Ng D., Salvatore S.P. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood. 2020;136:1169–1179. PubMed PMC

de Bont C.M., Boelens W.C., Pruijn G.J.M. NETosis, complement, and coagulation: a triangular relationship. Cell Mol Immunol. 2019;16:19–27. PubMed PMC

Barnes B.J., Adrover J.M., Baxter-Stoltzfus A., Borczuk A., Cools-Lartigue J., Crawford J.M. Targeting potential drivers of COVID-19: neutrophil extracellular traps. J Exp Med. 2020;217 PubMed PMC

Hidalgo A.A. NET-thrombosis axis in COVID-19. Blood. 2020;136:1118–1119. PubMed PMC

Varga Z., Flammer A.J., Steiger P., Haberecker M., Andermatt R., Zinkernagel A.S. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417–1418. PubMed PMC

Bonaventura A., Vecchié A., Dagna L., Martinod K., Dixon D.L., Van Tassell B.W. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat Rev Immunol. 2021:1–11. doi: 10.1038/s41577-021-00536-9. PubMed DOI PMC

Laffey J.G., Kavanagh B.P. Negative trials in critical care: why most research is probably wrong. Lancet Respir Med. 2018;6:659–660. PubMed

Girbes A.R.J., de Grooth H.-J. Time to stop randomized and large pragmatic trials for intensive care medicine syndromes: the case of sepsis and acute respiratory distress syndrome. J Thorac Dis. 2020;12(Suppl 1):S101–S109. doi: 10.21037/jtd.2019.10.36. PubMed DOI PMC

Figliozzi S., Masci P.G., Ahmadi N., Tondi L., Koutli E., Aimo A. Predictors of adverse prognosis in COVID-19: a systematic review and meta-analysis. Eur J Clin Invest. 2020;50 PubMed

De Backer D., Azoulay E., Vincent J.L. Corticosteroids in severe COVID-19: a critical view of the evidence. Crit Care. 2020;24:627. doi: 10.1186/s13054-020-03360-0. PubMed DOI PMC

Fischoff B. Making decisions in a COVID-19 world. JAMA. 2020;324:139–140. PubMed

Wang Y., Zhang D., Du G., Du R., Zhao J., Jin Y. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569–1578. PubMed PMC

Glaus M.J., Von Ruden S. Remdesivir and COVID-19. Lancet. 2020;396:952. PubMed PMC

Park J.J.H., Decloedt E.H., Rayner C.R., Cotton M., Molls E. Clinical trials of disease stages in COVID 19: complicated and often misinterpreted. Lancet Glob Health. 2020;8:1249. PubMed PMC

Ippolito G., Hui D.S., Ntoumi F., Maeurer M., Zumla A. Toning down the 2019-nCoV media hype—and restoring hope. Lancet Respir Med. 2020;8:230–231. PubMed PMC

Hunt K., Emslie C. Commentary: the prevention paradox in lay epidemiology--Rose revisited. Int J Epidemiol. 2001;30:442–446. PubMed

Rose G. Sick individuals and sick populations. Int J Epidemiol. 1985;14:32–38. PubMed

Editorial, Johnson R.M., Vinetz J.M. Dexamethasone in the management of covid-19. BMJ. 2020;370 PubMed

Saitz R., Schwitzer G. Communicating science in the time of a pandemic. JAMA. 2020;324:443–444. PubMed

COVID-19: a stress test for trust in science. Lancet. 2020;396:799. Editorial. PubMed PMC